Agilent Technologies, Inc. and Axion BioSystems, Inc. announced on April 21 2026 that they had reached a confidential settlement that resolves the litigation that had been pending in the United States District Court for the District of Delaware. The parties did not admit liability, and the terms of the agreement remain confidential.
The dispute centered on Agilent’s U.S. Patents 10,337,001 and 10,900,034, which cover specific chemical modifications to CRISPR guide RNAs, as well as patents 7,192,752, 7,468,255, and 8,026,080 that protect cell‑index calculation methods. Agilent alleged that Axion’s live‑cell analysis systems infringed these patents, while Axion maintained that its technology was independently developed and did not infringe.
In addition to the intellectual‑property claims, the lawsuit involved contractual matters that were not publicly disclosed in detail. The settlement therefore ends both the IP and contractual disputes that had been pending since the case was filed.
Agilent’s recent financial performance provides context for the settlement’s impact. In the first quarter of fiscal 2026, the company reported revenue of $1.80 billion, up 7.0 % year‑over‑year but slightly below analysts’ estimate of $1.81 billion. Non‑GAAP earnings per share were $1.36, missing the consensus estimate of $1.37 by $0.01, while GAAP net income fell 4 % year‑over‑year. The resolution of the litigation removes a potential legal distraction and allows Agilent to focus on its core business segments, particularly the Life Sciences and Diagnostics Markets Group, the CrossLab Group, and the Applied Markets Group.
Julien Bradley, CEO of Axion BioSystems, said, "We are pleased to have resolved this matter and to move forward without any impact on our products or business. Axion will continue, as we always have, to innovate our technology while respecting others' intellectual property and ensuring that our customers always have access to the very best tools for critical healthcare research notwithstanding the impact this may have on incumbents in our marketplace." The settlement therefore enables Axion to continue its innovation trajectory without the distraction and cost of ongoing litigation.
Overall, the confidential settlement removes a significant legal overhang for both companies. For Agilent, it eliminates a potential source of uncertainty that could have affected product development and market strategy, while for Axion it frees resources and focus for continued growth in live‑cell analysis technology. The settlement’s confidential terms mean that any financial impact on either company is not publicly disclosed, but the removal of the dispute is likely to be viewed positively by stakeholders who had been monitoring the case for potential risks to product pipelines and revenue streams.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.